Home › Funds › KVP Capital Advisors, LP › VRDN
KVP Capital Advisors, LP position in VRDN
VIRIDIAN THERAPEUTICS INC · Health Care
KVP Capital Advisors, LP reported holding 125,000 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$2.6M, representing 2.10% of its reported portfolio and ranking #19 among its reported holdings. KVP Capital Advisors, LP has disclosed VRDN holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How KVP Capital Advisors, LP's VRDN position evolved
KVP Capital Advisors, LP first disclosed a stake in VRDN in Q1 2026 at 125,000 shares (US$2.4M). The position peaked in Q3 2026 at 125,000 shares, worth US$2.6M. Across 3 filings, KVP Capital Advisors, LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 125,000 shares valued at US$2.6M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 125.00K | $2.44M | New |
| Q2 2026 | 125.00K | $2.30M | Hold |
| Q3 2026 | 125.00K | $2.57M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VRDN and 13F data
VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 43 other funds we track also report a position in VRDN — the largest reported positions include Paradigm Biocapital Advisors LP (US$227.1M), Kynam Capital Management, LP (US$126.6M), Bellevue Group AG (US$123.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRDN
- Paradigm Biocapital Advisors LP 12.41M sh · $227.08M · Q3 2026
- Kynam Capital Management, LP 6.15M sh · $126.59M · Q3 2026
- Bellevue Group AG 6.73M sh · $123.67M · Q2 2026
- RTW INVESTMENTS, LP 4.98M sh · $102.03M · Q3 2026
- Fairmount Funds Management LLC 5.09M sh · $93.52M · Q2 2026
- Deep Track Capital, LP 3.83M sh · $64.34M · Q3 2026
- Atlas Venture Life Science Advisors, LLC 4.50M sh · $61.83M · Q3 2026
- Venrock Adviser, LLC 3.26M sh · $59.85M · Q2 2026
- Context Capital Management, LLC 49.00M sh · $56.47M · Q3 2026
- Avoro Capital Advisors LLC 2.50M sh · $51.48M · Q3 2026
- BAKER BROS. ADVISORS LP 2.38M sh · $43.78M · Q2 2026
- Caligan Partners LP 2.19M sh · $40.30M · Q2 2026
More on KVP Capital Advisors, LP
FAQ
How long has KVP Capital Advisors, LP held VRDN?
KVP Capital Advisors, LP has disclosed VRDN holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is KVP Capital Advisors, LP's current position in VRDN?
As of Q3 2026, KVP Capital Advisors, LP holds 125.00K shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $2.57M, representing 2.10% of its reported portfolio and ranking #19.
Has KVP Capital Advisors, LP been buying or selling VRDN?
In the latest 13F filing (Q3 2026), KVP Capital Advisors, LP held unchanged its position in VRDN. The position peaked in Q3 2026 at 125.00K shares.
Which other funds hold VRDN?
Other major institutional holders of VRDN include Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, Bellevue Group AG, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.